Japan has formally enacted new legislation governing the development, approval and use of regenerative medicines, including induced pluripotent stem (iPS) cells, in a move welcomed by companies both inside and outside the country.
Japan has formally enacted new legislation governing the development, approval and use of regenerative medicines, including induced pluripotent stem (iPS) cells, in a move welcomed by companies both inside and outside the country.
The new regulatory regime involves revisions to the existing Pharmaceutical Affairs Law - now called the Pharmaceuticals, Medical Devices and Other Therapeutic Products
Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.
Join our China-based editors Dexter Yan and Xu Hu in this Chinese-language podcast looking at some of their recent interviews and other key coverage.
Biosimilars giant Celltrion tells shareholders there could be multiple opportunities for its business under US President Donald Trump’s latest executive order on drug pricing.
